Study findings updated . AI-assisted evidence summary, not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY1 in 5 COVID deathsShare of fatal COVID-19 cases linked to antibodies that disable interferon
Self-attacking antibodies against interferon appear in 18% of COVID deaths.
Interferons are the body's first alarm against viruses. Some people carry autoantibodies, antibodies aimed at their own proteins, that switch this alarm off. They were found in 18% of 1,124 people who died of COVID-19. Among uninfected people, they appeared in 1% of those under 70 but 6.3% of those over 80.
The antibodies were present before infection, not triggered by it, and grow more common with age. That helps explain why some older adults become so much sicker, and suggests a blood test could one day flag who most needs early treatment. The study links these antibodies to fatal COVID-19 and estimates their share of deaths, but it cannot prove they caused any individual death.
See the evidence
An international lab study, published in 2021, testing blood from 3,595 critically ill patients, 1,124 who died, and 34,159 uninfected people.
From the study: “These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years).”
1 in 5 COVID deaths
Bastard P et al. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths. Science immunology. 2021.
From the study: “1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years.”
1 in 5 COVID deaths
Bastard P et al. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths. Science immunology. 2021.
From the study: “They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases.”
1 in 5 COVID deaths
Bastard P et al. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths. Science immunology. 2021.
Long-acting antibody infusions cut COVID-19 cases for a year in a trial.
1.9% vs 11.9%Got sick with COVID-19 within 6 months: pemivibart vs. placebo
Pemivibart is a lab-made antibody built to last for months. In US adults without major immune problems who faced regular indoor exposure, two infusions were compared with placebo. Through 6 months, 1.9% of pemivibart recipients had symptomatic COVID-19, a COVID-19 hospital stay or died, versus 11.9% on placebo. Through 12 months: 4.7% versus 18.1%.
Earlier preventive antibodies stopped working as Omicron evolved, leaving people with weak immune systems few options. Pemivibart is already authorized in the US for some immunocompromised people, and here it prevented actual illness. These are interim results on an exploratory goal, and serious allergic reactions (anaphylaxis) occurred in 0.6% of people who received the drug.
See the evidence
A phase 3 trial at 18 US sites starting in 2023: 317 at-risk adults got pemivibart and 162 placebo, while 306 immunocompromised adults got pemivibart openly.
From the study: “In cohort B, 6 of 317 pemivibart (1.9%; no deaths) and 19 of 160 placebo (11.9%; no deaths) recipients met the end point through month 6”
1.9% vs 11.9%
Wolfe CR et al. Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025.
From the study: “15 of 317 pemivibart (4.7%; 1 death) and 29 of 160 placebo (18.1%; no deaths) recipients met the end point through month 12”
1.9% vs 11.9%
Wolfe CR et al. Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025.
From the study: “Four of 623 participants (0.6%) who received pemivibart experienced anaphylactic reactions (serious in 2).”
1.9% vs 11.9%
Wolfe CR et al. Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025.
New autoimmune diseases were diagnosed more often after COVID-19.
43% more autoimmunityHigher rate of new autoimmune disease after COVID-19, vs. matched uninfected people
Autoimmune diseases happen when the immune system attacks the body. In Germany, people with PCR-confirmed COVID-19 in 2020 had a 43% higher rate of a first autoimmune diagnosis in the following 3 to 15 months than matched people without COVID-19. In absolute terms, that was 4.50 extra cases per 1000 people per year.
The absolute increase is modest, but across millions of infections it adds up to many new long-term conditions. The link was strongest for vasculitis (blood-vessel inflammation) and after more severe COVID-19. Based on insurance billing records from before vaccines, this shows a link but cannot rule out that infected people were simply examined more closely.
See the evidence
A matched study of German health-insurance records for 641,704 people with COVID-19 in 2020, each matched to 3 uninfected people, followed into mid-2021.
From the study: “In the 3 to 15 months after acute infection, patients who had suffered from COVID-19 had a 43% (95% CI: 37-48%) higher likelihood of developing a first-onset autoimmune disease, meaning an absolute increase in incidence of 4.50 per 1000 person-years over the control group.”
43% more autoimmunity
Tesch F et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clinical Rheumatology. 2023. [Source notice: Correction published 2023-07-05 (10.1007/s10067-023-06692-8): figures 1 and 2 images were interchanged; legends unchanged.]
From the study: “Based on documented diagnoses, we identified individuals with polymerase chain reaction (PCR)-confirmed COVID-19 through December 31, 2020.”
43% more autoimmunity
Tesch F et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clinical Rheumatology. 2023. [Source notice: Correction published 2023-07-05 (10.1007/s10067-023-06692-8): figures 1 and 2 images were interchanged; legends unchanged.]
From the study: “The highest IRR was observed for autoimmune diseases of the vasculitis group.”
43% more autoimmunity
Tesch F et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clinical Rheumatology. 2023. [Source notice: Correction published 2023-07-05 (10.1007/s10067-023-06692-8): figures 1 and 2 images were interchanged; legends unchanged.]
MIS-C was rare but hit Black and Hispanic children far harder.
316 per millionMIS-C cases per million SARS-CoV-2 infections in people under 21, spring 2020
MIS-C is a dangerous, body-wide inflammation that can follow COVID-19 weeks later. In 7 US states in spring 2020, it occurred in about 316 of every million infections in people under 21. Compared with White youth, the rate per infection was 5.6 times higher in Black youth and 4.3 times higher in Hispanic or Latino youth (adjusted incidence rate ratios).
Knowing which children face the highest risk helps families and doctors act fast when a child develops high fever and signs of organ trouble weeks after an infection. Why the racial gap exists is still unknown. These estimates come from spring 2020, before vaccines and newer variants, and rely on modeled counts of total infections, so today's risk may differ.
See the evidence
A surveillance study, linked to CDC reporting, of 248 MIS-C cases in people under 21 across 7 US jurisdictions from April to June 2020.
From the study: “SARS-CoV-2 infections was 316 (95% CI, 278-357) persons and was higher among Black (aIRR, 5.62 [95% CI, 3.68-8.60]), Hispanic or Latino (aIRR, 4.26 [95% CI, 2.85-6.38])”
316 per million
Payne AB et al. Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2. JAMA network open. 2021.
New autoimmune diagnosis rates were higher after COVID-19
15.05 vs 10.55 per 1,000 person-years
In a matched German health-record study, new autoimmune diagnoses occurred at 15.05 per 1,000 person-years after COVID-19 versus 10.55 among people without COVID-19.
The comparison covered 2020 infections and diagnoses recorded 3–15 months later. This matched health-record association does not establish that infection caused the diagnoses.
Study details & original results
Tesch F et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clinical Rheumatology. 2023. [Source notice: Correction published 2023-07-05 (10.1007/s10067-023-06692-8): figures 1 and 2 images were interchanged; legends unchanged.]
New autoimmune diagnoses 3–15 months after COVID-19 in a matched German health-record study of 2020 infections, compared with people without COVID-19
15.05 vs 10.55 per 1,000 person-years 14.69–15.42 vs 10.25–10.86
Some JN.1 nonneutralizer sera regained detectable neutralization with complement
22 of 32
With complement, 22 of 32 sera classed as JN.1 nonneutralizers showed detectable JN.1 neutralization. Versus no added complement, serum neutralization titers increased against D614G, BA.1, XBB.1.5 and JN.1.
These are laboratory serum measurements. This summary does not identify the source or characteristics of the sera or provide clinical outcomes.
Study details & original results
Jungbauer-Groznica, Martin et al.. Complement augments antibody neutralization of SARS-CoV-2 variants.. Science translational medicine. 2026.
JN.1 nonneutralizer sera that regained detectable neutralization in the presence of complement
22 of 32
Increase in serum neutralization titers against D614G, BA.1, XBB.1.5, and JN.1 after complement was added
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 3 findingsOriginal results, comparisons and study details.
2 of 2 source groupsFindings stay together with their study.
SOURCE 031 finding
Tesch F et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clinical Rheumatology. 2023. [Source notice: Correction published 2023-07-05 (10.1007/s10067-023-06692-8): figures 1 and 2 images were interchanged; legends unchanged.]
Tesch F et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clinical Rheumatology. 2023. [Source notice: Correction published 2023-07-05 (10.1007/s10067-023-06692-8): figures 1 and 2 images were interchanged; legends unchanged.]
Bastard P et al. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths. Science immunology. 2021.
Wolfe CR et al. Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025.
Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results. Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed.
Download the findings and bibliography displayed in this page snapshot. Values and confidence intervals remain as reported text; this is not a pooled estimate or a systematic review. Product-label observations and editorial takeaways are excluded.
These findings may omit evidence or contain errors and have not been reviewed by a clinician. A citation or download does not establish source verification. Read the original studies for their methods and limitations.
The October 2026 COVID citation audit found errors in this collection. These downloads may still contain affected findings and bibliography entries. Read the correction record before using them.
“Added” dates record entry into the monitor, not publication or clinical review. A null original acquisition or derivation means its historical record is unknown; a current record or verification has its own observation time. The SHA-256 snapshot identifier binds the downloadable public fields. CSV includes finding rows and bibliography-only source rows; JSON includes both lists. Spreadsheet-sensitive CSV cells begin with an apostrophe for safety; JSON preserves the original text.
For attribution, cite ModernDoc and the page URL, data update date and snapshot identifier in the download. Original studies retain their own rights; this download does not grant a licence to their full text.